122 related articles for article (PubMed ID: 29069525)
1. Rapid onset of conjunctivitis associated with overdosing of erlotinib.
Sun P; Long J; Chen P; He Q; Gao X; Li S
J Clin Pharm Ther; 2018 Apr; 43(2):296-298. PubMed ID: 29069525
[TBL] [Abstract][Full Text] [Related]
2. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal perforations in patients treated with erlotinib: A report of two cases with fatal outcome and literature review.
Gass-Jégu F; Gschwend A; Gairard-Dory AC; Mennecier B; Tebacher-Alt M; Gourieux B; Quoix É
Lung Cancer; 2016 Sep; 99():76-8. PubMed ID: 27565918
[TBL] [Abstract][Full Text] [Related]
4. Newly recognized ocular side effects of erlotinib.
Methvin AB; Gausas RE
Ophthalmic Plast Reconstr Surg; 2007; 23(1):63-5. PubMed ID: 17237697
[TBL] [Abstract][Full Text] [Related]
5. Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).
Yamada K; Azuma K; Takeshita M; Uchino J; Nishida C; Suetsugu T; Kondo A; Harada T; Eida H; Kishimoto J; Eriguchi G; Takayama K; Nakanishi Y; Sugio K
Anticancer Res; 2016 Jun; 36(6):2881-7. PubMed ID: 27272800
[TBL] [Abstract][Full Text] [Related]
6. An open label phase II study evaluating first-line EGFR tyrosine kinase inhibitor erlotinib in non-small cell lung cancer patients with tumors showing high EGFR gene copy number.
Szutowicz-Zielińska E; Konopa K; Kowalczyk A; Suszko-Każarnowicz M; Duchnowska R; Szczęsna A; Ratajska M; Sowa A; Limon J; Biernat W; Burzykowski T; Jassem J; Dziadziuszko R
Oncotarget; 2017 Mar; 8(10):17270-17278. PubMed ID: 27924059
[TBL] [Abstract][Full Text] [Related]
7. A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients.
Suleiman AA; Frechen S; Scheffler M; Zander T; Nogova L; Kocher M; Jaehde U; Wolf J; Fuhr U
AAPS J; 2015 Nov; 17(6):1483-91. PubMed ID: 26286677
[TBL] [Abstract][Full Text] [Related]
8. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.
Parra-Guillen ZP; Berger PB; Haschke M; Donzelli M; Winogradova D; Pfister B; Früh M; Gillessen S; Krähenbühl S; Kloft C; Joerger M
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):309-315. PubMed ID: 28444958
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of erlotinib as a second line therapy for patients with epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC): our clinical experience.
Crvenkova S; Ivkovski Lj; Dimovski A; Kaeva B
Prilozi; 2012; 33(1):303-11. PubMed ID: 22983065
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old.
Bigot F; Boudou-Rouquette P; Arrondeau J; Thomas-Schoemann A; Tlemsani C; Chapron J; Huillard O; Cessot A; Vidal M; Alexandre J; Blanchet B; Goldwasser F
Invest New Drugs; 2017 Apr; 35(2):242-246. PubMed ID: 27796680
[TBL] [Abstract][Full Text] [Related]
11. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
12. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
13. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
[TBL] [Abstract][Full Text] [Related]
14. Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Fraser A
N Z Med J; 2017 Mar; 130(1451):11-20. PubMed ID: 28253240
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Kau HC; Tsai CC
Cutan Ocul Toxicol; 2016 Sep; 35(3):257-9. PubMed ID: 26340340
[TBL] [Abstract][Full Text] [Related]
17. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis.
Abdel-Rahman O; Fouad M
Expert Rev Anticancer Ther; 2015 Apr; 15(4):465-75. PubMed ID: 25664933
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka K; Suzumura T; Tsukuda H; Hasegawa Y; Ozaki T; Sugiura T; Fukuoka M
Anticancer Res; 2014 Sep; 34(9):5211-5. PubMed ID: 25202117
[TBL] [Abstract][Full Text] [Related]
19. Maintenance Treatment by Erlotinib and Toxic Cardiomyopathy: A Case Report.
Pinquié F; de Chabot G; Urban T; Hureaux J
Oncology; 2016; 90(3):176-7. PubMed ID: 26886479
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal thumbnail fissures due to erlotinib therapy for lung cancer.
Dasanu CA; Alvarez-Argote J; Lippman SM; Plaxe SC
J Oncol Pharm Pract; 2018 Apr; 24(3):229-231. PubMed ID: 28436313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
